JP2022526364A5 - - Google Patents

Info

Publication number
JP2022526364A5
JP2022526364A5 JP2021557761A JP2021557761A JP2022526364A5 JP 2022526364 A5 JP2022526364 A5 JP 2022526364A5 JP 2021557761 A JP2021557761 A JP 2021557761A JP 2021557761 A JP2021557761 A JP 2021557761A JP 2022526364 A5 JP2022526364 A5 JP 2022526364A5
Authority
JP
Japan
Prior art keywords
independently selected
substituted
pharmaceutically acceptable
acceptable salt
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526364A (ja
Filing date
Publication date
Priority claimed from GBGB1904373.6A external-priority patent/GB201904373D0/en
Application filed filed Critical
Publication of JP2022526364A publication Critical patent/JP2022526364A/ja
Publication of JP2022526364A5 publication Critical patent/JP2022526364A5/ja
Pending legal-status Critical Current

Links

JP2021557761A 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物 Pending JP2022526364A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1904373.6A GB201904373D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB1904373.6 2019-03-29
PCT/EP2020/058064 WO2020200900A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2022526364A JP2022526364A (ja) 2022-05-24
JP2022526364A5 true JP2022526364A5 (cg-RX-API-DMAC7.html) 2023-04-03

Family

ID=66442982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557761A Pending JP2022526364A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物

Country Status (18)

Country Link
US (1) US20220218679A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947378B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022526364A (cg-RX-API-DMAC7.html)
KR (1) KR20210145238A (cg-RX-API-DMAC7.html)
CN (1) CN113646305A (cg-RX-API-DMAC7.html)
AR (1) AR118521A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020252038A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019055A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134736A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014223A2 (cg-RX-API-DMAC7.html)
GB (1) GB201904373D0 (cg-RX-API-DMAC7.html)
IL (1) IL286677A (cg-RX-API-DMAC7.html)
MA (1) MA55497A (cg-RX-API-DMAC7.html)
MX (1) MX2021011576A (cg-RX-API-DMAC7.html)
PH (1) PH12021552375A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110644WA (cg-RX-API-DMAC7.html)
TW (1) TW202102501A (cg-RX-API-DMAC7.html)
WO (1) WO2020200900A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
CN113243338A (zh) * 2021-05-14 2021-08-13 福州大学 一种小鼠缺血性卒中模型的构建与评估方法
CN117177965B (zh) 2021-12-23 2024-04-30 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
EP4389747A1 (en) * 2022-12-21 2024-06-26 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
EP4638447A1 (en) * 2022-12-21 2025-10-29 Dark Blue Therapeutics Ltd Imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives as mllt1 and mllt3 inhibitors
CN119751445B (zh) * 2024-12-10 2025-11-25 江南大学 6-乙炔基吡唑并[1,5-a]吡啶的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
EP2688872A4 (en) * 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
GB201401086D0 (en) * 2014-01-23 2014-03-12 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CA2992406A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
GB201518456D0 (en) * 2015-10-19 2015-12-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2018083085A1 (en) * 2016-11-02 2018-05-11 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Similar Documents

Publication Publication Date Title
ES2289691T3 (es) Derivados de sulfonamida para el tratamiento de enfermedades.
AU2019260159B2 (en) HPK1 inhibitors, preparation method and application thereof
US20050197357A1 (en) Anticholinergics which may be used as medicaments as well as processes for preparing them
CN103987708B (zh) 4-羟基-1,2,3,4-四氢萘-1-基脲的衍生物及其在呼吸道疾病治疗中的用途
JP2015514794A (ja) 新規化合物
JP2015519319A (ja) 新規化合物
KR20130079379A (ko) 11(베타)-hsd1의 억제제로서 3,3-이치환된-(8-아자-비시클로[3.2.1]옥트-8-일)-[5-(1h-피라졸-4-일)-티오펜-3-일]-메탄온
CA2918284A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
CN103974953B (zh) 激酶抑制剂
EP4103564A1 (en) P2x3 modulators
JP7842612B2 (ja) 臭化ウメクリジニウムの調製プロセス
JP2019532054A (ja) Trpv4拮抗薬
JP2023532298A (ja) 化合物、組成物及び方法
JP2015528488A (ja) 脾臓チロシンキナーゼi(syk)阻害剤としての2−(2−アミノシクロヘキシル)アミノピリミジン−5−カルボキサミド類
JP2022526176A5 (cg-RX-API-DMAC7.html)
US20160168119A1 (en) Autotaxin inhibitors
CA3129851A1 (en) Substituted amide compounds useful as farnesoid x receptor modulators
CA3087994A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
JP2020500918A (ja) Nrf2レギュレーターとしてのn−アリールピラゾール
KR20100047333A (ko) 아세트아미드 입체이성체
AU2012277514A1 (en) Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders
CN102388025A (zh) 用作p38mapk抑制剂的嘧啶并哒嗪衍生物
CN107207407A (zh) 用于治疗疾病和病症的组合物和方法
EP1831210A1 (en) 8-aza-bicyclo[3.2.1]octane derivatives with an activity on chemokine ccr5 receptors
CN106232613A (zh) 选择性糖皮质激素受体配体